Medicus Pharma Ltd. (NASDAQ: MDCX)
Company Profile: Medicus Pharma Ltd. (NASDAQ: MDCX)
Last updated September 17, 2026. Figures are as reported by the company.
| Ticker / market | MDCX, Nasdaq |
|---|---|
| Headquarters | Philadelphia, Pennsylvania |
| Sector | Clinical-stage biotechnology |
| Lead programs | SkinJect (dermatologic oncology) and Teverelix (GnRH antagonist) |
| Website | medicuspharma.com |
What the company does
Medicus Pharma is a clinical-stage life sciences company that acquires and advances therapeutic assets through clinical development. It has no approved products and no product revenue. Its value rests on two development platforms.
Pipeline
- SkinJect: a dissolvable doxorubicin microneedle array patch being developed as a non-surgical treatment for basal cell carcinoma, developed through subsidiary SkinJect, Inc. In its Phase 2 study SKNJCT-003, the company reported clinical and histological clearance of 64% and 55%, respectively, at the 200 microgram dose. The company now describes the program as registrational Phase 2. The FDA has also authorized a study, SKNJCT-005, in Gorlin syndrome, a rare inherited condition that causes multiple basal cell carcinomas.
- Teverelix: a GnRH antagonist acquired through the Antev transaction, in Phase 2 development. The company reported IRB authorization and positive FDA feedback for an optimized study in preventing relapse of acute urinary retention, and authorization from the UAE Department of Health for the PRECISION-E2 study in endometriosis.
Financial snapshot (Q2 2026)
- Cash and cash equivalents of $15.2 million, compared with $9.7 million a year earlier.
- Net loss of $11.7 million, compared with $6.2 million a year earlier.
- Research and development expense of $4.9 million, compared with $1.4 million a year earlier.
- About $40 million raised year to date through an expanded at-the-market equity program and a secured financing facility.
Key risks to understand
- Going concern: the company disclosed that substantial doubt exists about its ability to continue as a going concern without additional financing.
- Dilution: operations are funded largely by selling new shares, including through the at-the-market program.
- Clinical and regulatory risk: Phase 2 results do not guarantee success in later studies or FDA approval, and timelines can slip.
- No product revenue: losses are widening as trial activity increases.
Sources
- Medicus Pharma second quarter 2026 results and corporate update (Aug. 12, 2026)
- Medicus Pharma clarifies SkinJect Phase 2 dataset (Apr. 1, 2026)
This profile is a factual summary compiled from company press releases and filings. It is not investment advice or a recommendation to buy or sell any security. See the compensation disclosure at the bottom of this page and our disclaimer.
Earlier Vanderbilt Report coverage
Transforming Oncology & Vaccine Therapeutics
Medicus Pharma Ltd. (NASDAQ: MDCX) is a clinical-stage, multi-strategy holding company dedicated to investing in innovative life sciences and biotechnology firms through FDA-approved clinical trials. The Company specializes in identifying, acquiring, and advancing relatively de-risked clinical-stage assets throughout their development and commercialization phases. To enhance its drug development pipeline, Medicus Pharma is actively pursuing acquisitions and strategic partnerships. Through its subsidiary, SkinJect, Inc., the Company is focused on developing a cutting-edge drug delivery system utilizing novel dissolvable microneedle arrays for the treatment of specific skin cancers. SkinJect represents a minimally invasive approach to treating common forms of non-melanoma skin cancer, including basal cell carcinoma and squamous cell carcinoma.
Vanderbiltreport Alert – This stock is a Sleeping Giant
Investment Highlights
Diversified Clinical Pipeline
– SkinJect / D-MNA Microneedle Patch – Phase
2 trial for basal cell carcinoma underway; FDA engagement progressing.
– Teverelix (via Antev Acquisition) – GnRH antagonist for prostate cancer & acute urinary
retention, addressing a $6B+ market opportunity.
– mRNA + Microneedle Collaboration (HelixNano) –
Thermostable vaccines for infectious diseases. Strong Financial Position
– $9.7M cash on hand (Q2 2025).
– Recently raised $4.2M via Reg A + $7.0M public offering.
– Acquisition structured with milestone-based payments, limiting dilution. Leadership &
Execution
– Proven biotech veterans onboard, including Patrick J. Mahaffy (Clovis Oncology, Pharmion).
– Strategic hires and Deloitte engaged to explore out-licensing opportunities.
Call your Broker now!
Market Opportunity
– Skin Cancer (Basal Cell Carcinoma): >5M new U.S. cases annually, ~$2B addressable market.
– Prostate Cancer & Urology: ~$6B+ combined global opportunity.
– Global Vaccines: Expanding market with delivery & distribution advantages.
Why Invest Now?
✔ Late-stage assets with clear regulatory milestones.
✔ Multiple shots on goal in oncology, urology, and vaccines.
✔ Strengthened balance sheet and capital-efficient acquisitions.
✔ Experienced team with track record of building and scaling biotechs.
Join us in building wealth, one investment at a time
Contact Investor Relations
DISCLAIMER
Vanderbiltreport.com is owned and operated by AB Holdings, SMG a US-based corporation. We have received compensation of up to $100,000 regarding the profiling of Medicus Pharma Ltd. (Nasdaq: MDCX) starting on Sept 5, 2025. It is important to note that we do not own any shares in MDCX: NASDAQ.
